Metabolic Disorders - Cysteamine (Oral) Products for Individual and Family Plans
Customize your policy alerts
Sign up for Cigna Policy IP0466 alerts
Get alerted when Policy IP0466 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, and documentation requirements for Cystagon and Procysbi for members on Cigna Individual and Family Plans for treatment of nephropathic cystinosis.
Criteria of approval were separated for Procysbi and Cystagon; Procysbi criteria now include a minimum age > 1 year.
Genetic confirmation language was clarified to require 'genetic testing confirmed biallelic pathogenic or likely pathogenic variants in the CTNS gene.'
A preferred product table for Individual and Family Plans was added, specifying prior trial/intolerance of Cystagon prior to Procysbi.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.